Celularity Inc. announced that it presented in vivo data from its T-cell therapy platform at this year?s ASCO Annual Meeting in Chicago. These data show that PT-CD16VS, Celularity?s T-Cell preclinical asset, has potent in vitro and in vivo activity and has the potential to be combined with various monoclonal antibodies to target multiple cancers. Celularity has adopted a ?universal receptor?

approach to develop a platform of genetically modified T-cells expressing a proprietary CD16 to be combined with various approved antibodies to address multiple cancers and other conditions. Data demonstrating PT-CD16VSs activity in combination with trastuzumab against HER2-positive cancers has already been presented at AACR in April. These data further build on this to demonstrate much broader potential across multiple hematological and solid tumors.